PS210 (PS-210) is a novel and potent activator (in vitro) or inhibitor (in cells) of protein kinase PDK1 with anticancer activity. It does not affect any of the 121 kinases, such as S6K, PKB/Akt, or GSK3, and instead targets the PDK1-interacting fragment (PIF)-binding pocket. PS210 is a powerful PDK1 activator in vitro, and the crystal structure of the PDK1-ATP-PS210 complex demonstrates that PS210 stimulates the kinase domain's closure. While not affecting PKB/Akt, the prodrug of PS210 (PS423) functions in cells as a substrate-selective inhibitor of PDK1, preventing the phosphorylation and activation of S6K, which requires docking to the PIF-pocket.
Physicochemical Properties
| Molecular Formula | C19H15F3O5 |
| Molecular Weight | 380.314616441727 |
| Exact Mass | 380.087 |
| Elemental Analysis | C, 60.00; H, 3.98; F, 14.99; O, 21.03 |
| CAS # | 1221962-86-2 |
| Related CAS # | (R)-PS210;1410101-89-1 |
| PubChem CID | 66760004 |
| Appearance | White to off-white solid powder |
| LogP | 3.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 27 |
| Complexity | 532 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | MLJPLHGJBUWCBA-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C19H15F3O5/c20-19(21,22)13-8-6-12(7-9-13)15(23)10-14(11-4-2-1-3-5-11)16(17(24)25)18(26)27/h1-9,14,16H,10H2,(H,24,25)(H,26,27) |
| Chemical Name | 2-(3-Oxo-1-phenyl-3-(4-(trifluoromethyl)phenyl)propyl)malonic acid |
| Synonyms | PS 210; PS-210; PS210 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | PDK1 (Kd = 3 μM) |
| ln Vitro | When PS210 causes PDK1 to stabilize at a specific temperature, PS210 stabilized the residue Arg131, which is located across from helix a-B at the opposite end of helix a-C. As a result, it appears that the residues constituting the phosphate-binding site are a fixed point that permits the relative movement of the helices during PDK1 activation[1]. |
| References |
[1]. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. [2]. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18590-5. |
Solubility Data
| Solubility (In Vitro) | DMSO: 76~100 mg/mL (199.8~262.9 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6294 mL | 13.1472 mL | 26.2943 mL | |
| 5 mM | 0.5259 mL | 2.6294 mL | 5.2589 mL | |
| 10 mM | 0.2629 mL | 1.3147 mL | 2.6294 mL |